HC Wainwright & Co. Reiterates Buy on Palatin Techs, Maintains $70 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Palatin Techs (AMEX:PTN) with a Buy and maintains $70 price target.
Earnings Outlook For Palatin Technologies
Palatin Technologies (AMEX:PTN) is set to give its latest quarterly earnings report on Wednesday, 2023-02-15. Here’s what investors…
Reported Earlier, Frontiers In Immunology Publishes Pre-Clinical Study Of Palatin’s PL8177 Demonstrating Therapeutic Effects In Inflammatory Conditions
- Collaboration with The William Harvey Research Institute and Queen Mary University of London
- PL-8177 displayed pro-resolving and anti-arthritic effects in rodents
CRANBURY,
Stocks That Hit 52-Week Lows On Thursday
Thursday's session saw 329 companies set new 52-week lows.
Earnings Scheduled For November 14, 2022
Companies Reporting Before The Bell
• Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on revenue of $3.68 million.
Palatin Net Product Revenue For Prescriptions Dispensed Increased 20%
Net product revenue for prescriptions dispensed increased 20%
Prescriptions dispensed increased 17%, over prior quarter
Refills accounted for over 50% of prescriptions dispensed
CRANBURY, N.J., Oct. 13, 2022
Looking Into Palatin Technologies’s Return On Capital Employed
Palatin Technologies (AMEX:PTN) brought in sales totaling $770 thousand during Q4 according to data provided by Benzinga Pro. However, earnings decreased 67.3%, resulting in a loss of $12.77 million.
Palatin Technologies: Q4 Earnings Insights
Palatin Technologies (AMEX:PTN) reported its Q4 earnings results on Thursday, September 22, 2022 at 07:30 AM.
Here's what investors need to know about the announcement.